Navigation Links
NIH to fund clinical research network on antibacterial resistance
Date:6/3/2013

Duke University, Durham, N.C., has been awarded $2 million to initiate a new clinical research network focused on antibacterial resistance. Total funding for the leadership group cooperative agreement award could reach up to $62 million through 2019. Funding is provided by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

"Antibacterial resistance is a serious and growing public health threat that is endangering the global medical community's ability to effectively treat conditions ranging from simple skin infections to tuberculosis," said NIAID Director Anthony S. Fauci, M.D. "Through this new clinical research network, we will strengthen our existing research capacity and address the most pressing scientific priorities related to antibacterial resistance."

Infections with bacteria resistant to antibiotic drugs were first reported more than 60 years ago. Since then, infections with resistant bacteria have become more common in health care and community settings, and many bacteria have become resistant to more than one type or class of antibiotics. As a result, medical professionals must treat infections with limited treatment options or, in some cases, when no effective antibiotics exist.

Co-led by principal investigators Vance Fowler, M.D., of Duke University, and Henry Chambers, M.D., of the University of California, San Francisco, the leadership group will design, implement and manage the network's clinical research agenda. In addition to the two principal investigators, the leadership group will include a consortium of more than 20 investigators nationwide with experience in diverse areas related to antibacterial resistance. The scientific efforts the leadership group is expected to undertake include:

  • Conducting early-stage clinical evaluation of new antibacterial drugs
  • Performing clinical trials to optimize currently licensed antibacterial drugs to reduce the risk of resistance
  • Testing diagnostics
  • Examining best practices in infection control programs to prevent the development and spread of resistant infections

An operations center at Duke University will anchor the network and provide administrative and technical support, a laboratory center, and a statistics and data management center. The network will address the priority areas identified in its clinical research agenda using existing NIAID clinical trials infrastructure, including the clinical trial units that support NIAID's HIV/AIDS clinical trials networks and Vaccine and Treatment Evaluation Units.

Planning for the development of the new NIAID clinical trials network on antibacterial resistance began in 2010 in connection with a larger effort to restructure NIAID's HIV/AIDS clinical trials networks. NIAID conducted extensive consultations with infectious disease researchers, clinicians, nurses, and patient advocates in moving forward with the concept. This award will complement NIAID's extensive antimicrobial resistance portfolio, which includes clinical research and product development, as well as clinical trials evaluating optimal utilization strategies for currently available antibacterial drugs.


'/>"/>

Contact: Jennifer Routh
Jennifer.Routh@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. Clinical insight improves treatment with new lung cancer drug
3. Clinical news alert from the American Academy of Orthopaedic Surgeons
4. NYU Langone experts present research, clinical advances at neurosurgeons meeting
5. Kroenke honored for outstanding contributions in clinical research training
6. Awards celebrate clinical research that can improve health and alleviate suffering
7. Association for Psychological Science, SAGE launch Clinical Psychological Science
8. URMC clinical trial tests new regimen for hypertension
9. Analysis Finds Clinical Trials Often Small, of Poor Quality
10. Automated insulin dosage titration system demonstrates positive clinical study results
11. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... , ... February 17, 2017 , ... Butler Mobility invited ... Stannah Stairlift and other Butler products. Ken was impressed with the safety and ... to endorse the product on his show. This endorsement by Ken Matthews can ...
(Date:2/17/2017)... ... 2017 , ... Smiles by Seese is a comprehensive family dental practice ... leads the practice as a skilled and highly credentialed dentist who is qualified to ... patients of all ages with excellence in general, restorative, and cosmetic dentistry . ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Webinar**, Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, ... be asking before selecting an FDA approval pathway? , How should they ...
(Date:2/17/2017)... ... 2017 , ... Program will serve more than 5,000 kids ... Soccer Foundation announced today that they have awarded nine grants to expand the ... soccer mentoring program, teaches kids the fundamentals of soccer while striving to help ...
(Date:2/17/2017)... ... February 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial ... by the Hospital Readmission Reduction Program (HRRP), the return of a patient to the ... across the nation. While many providers are struggling to leverage limited resources and technology, ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... Research and Markets has announced the addition of the "Contraceptives - ... ... the US, Canada , Japan , ... Latin America , and Rest of World. Annual estimates and forecasts ... analysis is provided for these markets. Market data and analytics are derived ...
(Date:2/17/2017)...  Ethicon, Inc. today announced a definitive agreement ... medical device company that manufactures and markets the ... minimally invasive device for the surgical treatment of ... Ethicon to offer patients a safe and effective ... procedure. 1 This LINX ® ...
(Date:2/17/2017)... 2017 Theravance Biopharma, Inc. (NASDAQ: ... today announced the presentation of positive clinical data ... pan-Janus kinase (JAK) inhibitor designed to be intestinally ... the European Crohn,s and Colitis Organization (ECCO). In ... from its completed Phase 1 study of single-ascending ...
Breaking Medicine Technology: